New combo attack: CAR T-Cells plus radiation takes on tough lymphoma
NCT ID NCT06043323
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial is testing whether combining a CAR T-cell therapy (axicabtagene ciloleucel) with radiation therapy is safe for people with follicular lymphoma that has returned or not responded to at least two prior treatments. About 20 adults will receive the treatment, and researchers will monitor side effects closely. The goal is to see if this combination can be a new option for hard-to-treat cases.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
axicabtagene ciloleucel (CAR T-cell therapy)
What this could lead to
If successful, this combination could offer a new treatment option for people with follicular lymphoma that has stopped responding to standard therapies.
What could go wrong
This is a small, early-phase trial (20 people) focused on safety, not yet proven to work. CAR T-cell therapy can cause serious side effects like cytokine release syndrome and neurological problems.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FOLLICULAR LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••